Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies

by Procopio, G, Verzoni, E, Iacovelli, R, Biasoni, D, Testa, I, Porcu, L, De Braud, F
Published 2012

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial

by Procopio, G, Verzoni, E, Bracarda, S, Ricci, S, Sacco, C, Ridolfi, L, Porta, C, Miceli, R, Zilembo, N, Bajetta, E
Published 2011

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis

by Procopio, G, Bellmunt, J, Dutcher, J, Bracarda, S, Knox, J, Brueckner, A, Molnar, I, Escudier, B, Hutson, T E
Published 2013